Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Triesence · 1 trial · 1 indication
Intraocular pressure (IOP) was measured by applanation tonometry in millimeters of mercury (mmHg). Surgical success was determined if IOP was \<21mmHg and 20% less than baseline IOP. Failure was defined as inability to meet criteria for success or IOP was less than 5mmHg.
| Arm | Type | Description |
|---|---|---|
| Treatment 1(Triesence) | EXPERIMENTAL | glaucoma surgery with 0.2cc Triesence adjunct. |
| Treatment 2 (balanced salt solution BSS) | ACTIVE_COMPARATOR | glaucoma surgery with balanced salt solution, the standard technique. |
| Name | Type | Description |
|---|---|---|
| Triesence | DRUG | At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound. |
| balanced salt solution BSS | DRUG | At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure. |
Inclusion Criteria: * glaucoma patients requiring surgery (Trabeculectomy or Express Shunt; Trabeculectomy plus Phacoemulsification and Interocular Lens Implant; Baerveldt Tube; Ahmed Tube; Molteno Tube) * primary open angle glaucoma * primary angle-closure glaucoma * pseudoexfoliation glaucoma * p...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
Triesence is an investigational small molecule being studied for use in glaucoma. It is being evaluated for its ability to lower eye pressure during glaucoma surgery and improve surgical outcomes. The drug is in Phase 2 clinical development and is not yet approved for this use.
Triesence is being developed by Alcon Inc., a company traded under the ticker ALC. Alcon is conducting clinical research on the drug for the treatment of glaucoma.
Triesence is in Phase 2 clinical development. It is an investigational drug for glaucoma and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed.
Triesence has been studied in a completed Phase 2 clinical trial with the identifier NCT00853905. This trial enrolled 77 participants in the United States and evaluated the drug's use during glaucoma surgery to lower eye pressure and improve surgical results.
Triesence is a distinct investigational drug being developed by Alcon Inc. for glaucoma. It is being studied as an adjunct to glaucoma surgery, with the goal of reducing eye pressure and enhancing surgical outcomes.